Ryan Mitteness

206-389-4533
rmitteness@fenwick.com
Partner
Corporate

Ryan
Mitteness

Ryan
Mitteness

Ryan
Mitteness

Partner
Corporate
Industries

Ryan advises clients in the life sciences and technology industries on capital markets and corporate matters. He has worked closely with executives, boards of directors and underwriters to provide thoughtful counseling in capital market transactions and corporate governance matters. Ryan’s extensive experience includes representing companies, primarily in the life sciences, investors and underwriters in all manner of capital market transactions, including IPOs, reverse mergers, ATM offerings, PIPE offerings, SPAC mergers, convertible debt and other financings. Ryan also advises public companies on various general corporate and securities law matters, including corporate governance best practices, ESG best practices, compliance with stock exchange rules and securities laws, and periodic reporting obligations.

Ryan has previously worked at two global law firms, where his practice focused on capital markets and corporate governance.

During law school, Ryan was an articles editor for The George Washington Law Review.

Read more

  • Amyris
  • AnaptysBio
  • Chinook Therapeutics
  • Elevation Oncology
  • Impel
  • Gitlab
  • Gritstone Bio
  • Maze Therapeutics
  • Passage Bio
  • Redmile Group
  • Sutro BioPharma
  • Third Harmonic

  • Amyris
  • AnaptysBio
  • Chinook Therapeutics
  • Elevation Oncology
  • Impel
  • Gitlab
  • Gritstone Bio
  • Maze Therapeutics
  • Passage Bio
  • Redmile Group
  • Sutro BioPharma
  • Third Harmonic

  • Third Harmonic in its initial public offering
  • Elevation Oncology in its initial public offering and PIPE offerings
  • Impel Pharmaceuticals in its initial public offering and follow-on offering
  • GitLab Inc. in its initial public offering
  • Passage Bio in its initial public offering and follow-on offerings
  • Chinook Therapeutics in its reverse merger transaction, follow-on offerings and sale to Novartis.
  • Neoleukin Therapeutics in its reverse merger transaction
  • Amryis Inc. in its follow-on offerings, PIPE offerings and convertible notes offering
  • Aeglea Biotherapeutics in its follow-on offerings
  • Sutro Biopharma in its follow-on offerings
  • Fluidigm Corporation in its convertible notes offering

  • Third Harmonic in its initial public offering
  • Elevation Oncology in its initial public offering and PIPE offerings
  • Impel Pharmaceuticals in its initial public offering and follow-on offering
  • GitLab Inc. in its initial public offering
  • Passage Bio in its initial public offering and follow-on offerings
  • Chinook Therapeutics in its reverse merger transaction, follow-on offerings and sale to Novartis.
  • Neoleukin Therapeutics in its reverse merger transaction
  • Amryis Inc. in its follow-on offerings, PIPE offerings and convertible notes offering
  • Aeglea Biotherapeutics in its follow-on offerings
  • Sutro Biopharma in its follow-on offerings
  • Fluidigm Corporation in its convertible notes offering